Omeros (NASDAQ:OMER) Director Sells $87,075.00 in Stock

Omeros Corporation (NASDAQ:OMER) Director Thomas Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director owned 35,067 shares in the company, valued at $407,127.87. This represents a 17.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Trading Down 1.0%

NASDAQ OMER opened at $11.04 on Friday. The stock’s 50 day moving average is $12.30 and its two-hundred day moving average is $11.70. The company has a market capitalization of $799.08 million, a price-to-earnings ratio of 15.77 and a beta of 2.66. Omeros Corporation has a 1-year low of $2.95 and a 1-year high of $17.65.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. On average, analysts predict that Omeros Corporation will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on OMER. Weiss Ratings raised Omeros from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Omeros in a report on Thursday, May 14th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, April 21st. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Finally, Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Omeros presently has a consensus rating of “Buy” and an average price target of $40.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of OMER. UBS Group AG boosted its holdings in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after acquiring an additional 1,513,893 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after acquiring an additional 666,357 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after acquiring an additional 384,168 shares in the last quarter. State Street Corp boosted its holdings in shares of Omeros by 26.9% in the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after acquiring an additional 333,798 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Omeros by 39.3% in the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.